PARP Inhibitors in Ovarian Cancer: Role, Testing and Resistance
On this page
PARP Inhibitors in Ovarian Cancer: Mechanisms, Eligible Patients, and Understanding Resistance
PARP inhibitors are targeted therapies pivotal in certain ovarian cancer scenarios, mainly serving as maintenance options after a favorable response to platinum-based chemotherapy. Their use hinges on factors like the tumor’s BRCA status, presence of homologous recombination deficiency (HRD), patient history, and other clinical considerations.
What Are PARP Inhibitors?
A PARP inhibitor disrupts PARP proteins, crucial for repairing specific DNA damage in cells. By obstructing PARP, these drugs prevent cancer cells from effectively fixing their DNA, which can ultimately lead to cancer cell death.
This strategy is especially effective in cancers where the homologous recombination repair pathway is already compromised—commonly seen in tumors with BRCA mutations. When both repair systems are weakened, cancer cells accumulate DNA errors and may not survive.
PARP inhibitors embody the precision medicine approach, matching treatment to the molecular characteristics of both the tumor and the patient.
How Are PARP Inhibitors Used in Ovarian Cancer?
Their primary role is as maintenance therapy following a complete or partial tumor response to platinum-based chemotherapy. Maintenance treatment aims to sustain disease control rather than treat ongoing, visible progression.
Treatment decisions regarding PARP inhibitors are based on a range of factors:
- Ovarian cancer subtype and stage
- Response to platinum chemo
- BRCA and HRD status
- Prior therapies and side-effect risks
- Overall treatment goals
Various PARP inhibitors—like olaparib, niraparib, and rucaparib—are available, each with unique approvals and biomarker requirements. The gynecologic oncology team evaluates whether a patient is a fit for these drugs.
Who Might Benefit Most From PARP Inhibitors?
Eligibility typically depends on the tumor having BRCA1/BRCA2 mutations or signs of HRD. Such cancers rely more heavily on the PARP repair mechanism, making them more vulnerable when it’s inhibited.
Key eligibility considerations include:
- Germline or tumor BRCA mutations
- HRD test results
- Genomic instability scores
- Response to platinum therapy
- Previous PARP inhibitor exposure
- Ability to tolerate treatment
Guidelines recommend PARP inhibitor maintenance after a good response to platinum-based chemotherapy for specific groups, particularly BRCA-mutated or HRD-positive cases, verified through approved diagnostic tests.
What Tests Are Required Before Starting PARP Inhibitors?
- BRCA Testing:Identifies pathogenic variants in BRCA1/2—either inherited (via blood/saliva) or acquired in tumor tissue. A positive result signals a vulnerability in DNA repair, supporting PARP inhibitor use after platinum response.
- HRD Testing:Assesses the tumor’s capability to repair DNA via the homologous recombination pathway, using data from genomic instability and related molecular findings.
These molecular insights are evaluated alongside diagnosis, stage, previous treatments, and platinum response to determine potential benefit from PARP inhibitors.
PARP Inhibitors as Maintenance Therapy
In maintenance settings, PARP inhibitors are started after chemotherapy has stabilized the disease, aiming to maintain that response and delay recurrence or progression. Their suitability may be limited by:
- Previous use of PARP inhibitors
- Platinum-resistant disease
- Significant side effects
Mechanism of Action in Ovarian Cancer
Cells continuously endure DNA damage and depend on repair systems. PARP proteins fix single-stranded breaks; blocking them leads to unrepaired damage. If a tumor already has BRCA or HRD-associated deficiencies, adding a PARP inhibitor creates a critical vulnerability—causing irreparable DNA damage and cancer cell death.
Thus, PARP inhibitors have heightened efficacy in tumors with DNA-repair defects compared to those with intact repair pathways.
Understanding PARP Inhibitor Resistance
Over time, some ovarian cancers develop resistance to PARP inhibitors—meaning the cancer no longer responds despite ongoing therapy.
- Common resistance mechanisms include:Restoration of homologous recombination repair (often via secondary “reversion” mutations in BRCA1/2) Stabilization of DNA replication forks Reduced drug trapping Enhanced drug efflux Adaptations in DNA-damage-response pathways or tumor microenvironment
Typically, resistance is multifaceted. Research continues on overcoming resistance, including combining treatments and investigating clinical trials, always tailored to individual circumstances.
Monitoring PARP Inhibitor Response
- Patient response is tracked through:Clinical and symptom assessment Physical exams Imaging techniques (CT, PET-CT) Blood tests for safety, organ function, and occasionally tumor markers (e.g., CA-125, though not used alone for decisions)
When disease progresses, molecular testing may be used to understand resistance and evaluate other treatment or trial options.
Key Takeaways PARP inhibitors block a critical DNA-repair pathway, working especially well in BRCA-mutated or HRD-positive ovarian cancers. Their main use is as maintenance therapy after a clear response to platinum-based chemotherapy. NGS, BRCA, and HRD testing help oncologists tailor treatment. Eligibility depends on biomarkers, platinum response, prior treatments, and patient factors. Cancer may develop resistance to PARP inhibitors, often via restored DNA repair or other adaptations.